Table 2.
Efficacy of MIGS devices.
| Author | Year | Operation | Number of eyes | Follow-up (months) | Preop IOP (mmHg) | Postop IOP (mmHg) | IOP reduction (mmHg, %)∗ | Preop meds | Postop meds | Medication reduction (n, %)∗ |
|---|---|---|---|---|---|---|---|---|---|---|
| Schlemm's canal devices∗∗ | ||||||||||
| Trabectome | ||||||||||
| Wecker et al. [39] | 2016 | Trabectome ± CS | 60 | 12 | 24.5 ± 3.5 | 15.7 ± 3.4 | 8.8 (35.9) | 2.1 ± 1.3 | 1.8 ± 1.2 | 0.3 (14.3) |
| Lee et al. [38] | 2016 | Trabectome | 17 | 6 | 24.4 ± 4.4 | 16.9 ± 5.1 | 7.5 (30.7) | 3.9 ± 0.8 | 2.8 ± 1.6 | 1.1 (28.2) |
| Jordan et al. [40] | 2013 | Trabectome ± CS | 261 | 6 | 24.2 ± 5.5 | 18.2 ± 6.1 | 6 (24.8) | 2.1 ± 1.3 | 1.2 ± 1.1 | 0.9 (42.9) |
| Bussel et al. [37] | 2015 | Trabectome | 58 | 12 | 23.7 ± 5.5 | 16.2 ± 3.9 | 7.5 (31.6) | 2.8 ± 1.2 | 2.0 ± 1.3 | 0.8 (28.6) |
| Trabectome ± CS | 15 | 12 | 20 ± 5.9 | 15.6 ± 5.1 | 4.4 (22.0) | 2.5 ± 1.5 | 1.6 ± 1.4 | 0.9 (36.0) | ||
| Maeda et al. [64] | 2013 | Trabectome | 80 | 6 | 26.6 ± 8.1 | 17.4 ± 3.4 | 9.2 (34.6) | 4.0 ± 1.4 | 2.3 ± 1.2 | 1.7 (42.5) |
| Ting et al. [36] | 2012 | Trabectome | 450 | 12 | 25.5 ± 7.9 | 16.8 ± 3.9 | 8.7 (34.1) | 2.7 ± 1.3 | 2.2 ± 1.3 | 0.5 (20.9) |
| Trabectome | 67 | 12 | 29 ± 7.5 | 16.1 ± 4.0 | 12.9 (44.5) | 3.1 ± 1.2 | 2.2 ± 1.4 | 0.8 (28.5) | ||
| Trabectome ± CS | 263 | 12 | 19.9 ± 5.4 | 15.6 ± 3.2 | 4.3 (21.6) | 2.4 ± 1.1 | 1.7 ± 1.3 | 0.8 (31.3) | ||
| Trabectome ± CS | 45 | 12 | 21.7 ± 8.4 | 14.2 ± 3.1 | 7.5 (34.6) | 2.5 ± 1.0 | 1.6 ± 1.3 | 1.0 (37.9) | ||
| Francis et al. [42] | 2008 | Trabectome ± CS | 304 | 12 | 20 ± 6.3 | 15.5 ± 2.9 | 4.5 (22.5) | 2.7 ± 1.1 | 1.4 ± 1.3 | 1.2 (45.7) |
| Minckler et al. [35] | 2005 | Trabectome | 37 | 12 | 28.2 ± 4.4† | 16.3 ± 2.0 | 11.9 (42.2) | 1.2 ± 0.6 | 0.4 ± 0.6 | 0.8 (66.7) |
|
| ||||||||||
| ELT | ||||||||||
| Babighian et al. [49] | 2010 | ELT | 15 | 24 | 25.0 ± 1.9 | 17.6 ± 2.2 | 7.4 (29.6) | 2.2 ± 0.6 | 0.7 ± 0.8 | 1.5 (66.8) |
| Wilmsmeyer et al. [48] | 2006 | ELT | 75 | 12 | 23.3 ± 0.6 | 18.8 ± 0.8 | 4.5 (19.3) | 1.9 ± 0.1 | 1.8 ± 0.2 | 0.1 (5.3) |
| ELT + CS | 60 | 12 | 22.4 ± 0.8 | 16.4 ± 0.4 | 6.0 (26.8) | 1.1 ± 0.2 | 1.2 ± 0.2 | −0.1 (−9.1) | ||
|
| ||||||||||
| iStent | ||||||||||
| Vold et al. [15] | 2016 | 2 iStents | 54 | 36 | 25.5 ± 2.5 | 14.6 | 10.9 (42.7) | 0 | 0.1 | −0.1 |
| Katz et al. [7] | 2015 | 1 iStent | 38 | 18 | 19.8 ± 1.3 | 15.6 ± 1.5 | 4.2 (21.2) | 1.7 + 0.6 | 0.18 | 1.5 (89.5) |
| 2 iStents | 41 | 18 | 20.1 ± 1.6 | 13.8 ± 1.3 | 6.3 (31.3) | 1.8 ± 0.5 | 0.12 | 1.6 (93.2) | ||
| 3 iStents | 40 | 18 | 20.4 ± 1.8 | 12.1 ± 1.2 | 8.3 (40.7) | 1.5 ± 0.7 | 0.08 | 1.4 (94.7) | ||
| Craven et al. [17] | 2012 | 1 iStent + CS | 116 | 24 | 18.6 ± 3.4 | 17.1 ± 2.9 | 1.5 (8.1) | 1.6 ± 0.8 | 0.3 ± 0.6 | 1.3 (81.3) |
| Fea [19] | 2010 | 1 iStent + CS | 12 | 16 | 17.9 ± 2.6 | 16.6 ± 3.1 | 1.3 (7.3) | 2 ± 0.9 | 0 | 2 (100) |
| Fernandez-Barrientos et al. [13] | 2010 | 2 iStents + CS | 17 | 12 | 24.2 ± 1.8† | 17.6 ± 2.8 | 6.6 (27.3) | 1.1 ± 0.5 | 0 | 1.1 (100) |
| Lindstrom et al. [16] | 2016 | 2 iStents | 57 | 18 | 19.5 ± 1.5 | 14.4 ± 2.1 | 5.1 (26.2) | 1 | 0.02 | 0.98 (98.0) |
| Tan and Au [23] | 2016 | 1 iStent + CS | 41 | 36 | 21.2 ± 4.7 | 17.1 ± 2.4 | 4.1 (19.3) | 2.1 ± 1.0 | 1.3 ± 1.2 | 0.8 (38.1) |
| Donnenfeld et al. [10] | 2015 | 2 iStents | 39 | 36 | 20.6 ± 2.0 | 14.2 ± 2.1 | 6.4 (31.1) | 1 | 0.05 | 0.95 (95.0) |
| Fea et al. [20] | 2015 | 1 iStent + CS | 10 | 48 | 17.8 ± 2.7 | 15.9 ± 2.3 | 1.9 (10.7) | 1.9 ± 0.9 | 0.5 ± 0.8 | 1.4 (74.7) |
| Neuhann [22] | 2015 | 1 iStent + CS | 62 | 36 | 24.1 ± 6.9 | 14.9 ± 2.3 | 9.2 (38.2) | 1.8 ± 0.9 | 0.3 ± 0.5 | 1.5 (83.3) |
| Ahmed et al. [11] | 2014 | 2 iStents | 39 | 12 | 22.2 ± 2.0 | 17.1 ± 2.2 | 5.1 (23.0) | 2 | 1 | 1 (50.0) |
| Arriola-Villalobos et al. [12] | 2013 | 2 iStents + CS | 20 | 12 | 20.0 ± 3.7 | 16.8 ± 2.2 | 3.2 (16.0) | 1.3 ± 0.7 | 0.3 ± 0.6 | 1 (76.9) |
| Patel et al. [26] | 2013 | 1 iStent ± CS | 44 | 6 | 21.5 | 16.7 | 4.8 (22.3) | 2.3 | 0.6 | 1.7 (73.9) |
| Arriola-Villalobos et al. [25] | 2012 | 1 iStent + CS | 19 | 36 | 19.4 ± 1.9 | 16.3 ± 4.2 | 3.2 (16.3) | 1.3 ± 0.5 | 0.8 ± 0.9 | 0.48 (36.4) |
| Buchacra et al. [9] | 2011 | 1 iStent | 10 | 12 | 26.5 ± 7.9 | 17.0 ± 2.5 | 9.5 (35.8) | 2.9 ± 0.7 | 1.1 ± 0.6 | 1.8 (62.1) |
| Samuelson et al. [18] | 2011 | 1 iStent + CS | 111 | 12 | 18.4 ± 3.2 | 16.9 ± 3.0 | 1.5 (8.2) | 1.5 ± 0.6 | 0.2 ± 0.6 | 1.3 (86.7) |
| Vandewalle et al. [24] | 2009 | 1 iStent ± CS | 10 | 12 | 19.6 | 15.8 | 3.8 (19.4) | 2.7 | 1.7 | 1 (37.0) |
| Spiegel et al. [27] | 2009 | 1 iStent ± CS | 47 | 12 | 21.5 ± 3.7 | 16.9 | 4.6 (21.4) | 1.6 ± 0.8 | 0.4 | 1.2 (75.0) |
|
| ||||||||||
| iStent inject | ||||||||||
| Fea et al. [28] | 2014 | 2 iStent injects | 94 | 12 | 21.1 ± 1.7 | 13.0 ± 2.3 | 8.1 (38.4) | 1 | 0.1 | 0.9 (91.5) |
| Arriola-Villalobos et al. [30] | 2016 | 1 iStent inject + CS | 11 | 60 | 20.4 ± 4.5 | 16.2 ± 2.3 | 4.2 (20.5) | 1.2 ± 0.8 | 1.1 ± 0.8 | 0.1 (7.6) |
| Voskanyan et al. [29] | 2014 | 2 iStent injects | 99 | 12 | 22.1 ± 3.3 | 15.7 ± 3.7 | 6.4 (29.0) | 2.2 ± 0.4 | 0.3 | 1.9 (87.3) |
| Gonnermann et al. [31] | 2016 | 2 iStent injects + CS | 25 | 12 | 21.3 ± 4.1 | 14.0 ± 2.3 | 7.3 (34.0) | 2.0 ± 0.9 | 1.3 ± 1.2 | 0.7 (36.0) |
| Klamann et al. [65] | 2015 | 1 iStent inject†† | 17 | 6 | 21.2 ± 2.6 | 14.2 ± 1.4 | 7 (33.0) | 2.2 ± 0.9 | 0.9 ± 0.6 | 1.3 (59.8) |
| 1 iStent inject†† | 15 | 6 | 23.8 ± 3.3 | 15.3 ± 1.1 | 8.4 (35.5) | 2.3 ± 1.2 | 1.0 ± 0.3 | 1.3 (55.4) | ||
| 1 iStent inject†† | 3 | 6 | 28.3 ± 3.2 | N.A. | N.A. | N.A. | N.A. | N.A. | ||
|
| ||||||||||
| Hydrus | ||||||||||
| Pfeiffer et al. [32] | 2015 | Hydrus + CS | 50 | 24 | 18.9 ± 3.3 | 16.9 ± 3.3 | 2.0 (10.6) | 2.0 ± 1.0 | 0.5 ± 1.0 | 1.5 (75.0) |
| Fea et al. [33] | 2016 | Hydrus | 31 | 12 | 23.1 ± 5.1 | 16.5 ± 2.6 | 6.6 (28.5) | 2.3 ± 0.8 | 0.9 ± 1.0 | 1.4 (60.7) |
| Gandolfi et al. [34] | 2016 | Hydrus | 21 | 24 | 26.0 ± 4.0 | 16.0 ± 2.0 | 10.0 (38.5) | 2.7 | 0.9 ± 1.0 | 1.8 (66.9) |
|
| ||||||||||
| Suprachoroidal devices | ||||||||||
| CyPass | ||||||||||
| Vold et al. [15] | 2016 | CyPass + CS | 374 | 24 | 24.4 ± 2.8† | 17.0 ± 3.4 | 7.4 (30.3) | 1.4 ± 0.9 | 0.2 ± 0.6 | 1.2 (85.7) |
| Hoeh et al. [53] | 2016 | CyPass + CS | 142 | 12 | 20.2 ± 6.0 | 15.9 ± 3.1 | 4.3 (21.3) | 2.0 ± 1.1 | 1.1 | 0.9 (45.0) |
| Garcia-Feijoo et al. [54] | 2015 | CyPass | 65 | 12 | 24.5 ± 2.8 | 16.4 ± 5.5 | 8.1 (33.1) | 2.2 ± 1.1 | 1.4 ± 1.3 | 0.8 (36.4) |
| Hoeh et al. [52] | 2013 | CyPass + CS | 184 | 6 | 21.1 ± 5.9 | 15.6 ± 0.5 | 5.5 (26.1) | 2.1 ± 1.1 | 0.8 | 1.35 (64.3) |
|
| ||||||||||
| Subconjunctival devices | ||||||||||
| XEN-45 | ||||||||||
| Perez-Torregrosa et al. [55] | 2016 | XEN-45 + CS | 30 | 12 | 21.2 ± 3.4 | 15.0 ± 2.5 | 6.2 (29.1) | 3.1 ± 0.7 | 0.2 ± 0.7 | 2.9 (94.5) |
|
| ||||||||||
| InnFocus | ||||||||||
| Batlle et al. [63] | 2016 | InnFocus ± CS | 23 | 36 | 23.8 ± 5.3 | 10.7 ± 3.5 | 13.1 (55.0) | 2.4 ± 1.0 | 0.7 ± 1.1 | 1.7 (70.8) |
CS: cataract surgery; ELT: excimer laser trabeculotomy; IOP: intraocular pressure; ∗ represents unpaired results; ∗∗ represents only prospective case series and randomized controlled trials are included; † represents postwashout IOP; †† represents study was split into three groups: phakic open-angle glaucoma, phakic pseudoexfoliation glaucoma, and pseudophakic subjects, respectively.